Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives.
about
Path to the clinic: assessment of iPSC-based cell therapies in vivo in a nonhuman primate model.Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem CellsPerspectives on the use of stem cells for autism treatmentAvoiding immunological rejection in regenerative medicine.Overcoming immunological barriers in regenerative medicine.Quiescent Tissue Stem Cells Evade Immune Surveillance.Preclinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies.
P2860
Q33760206-E43FB08A-924E-4087-AC27-D07C7048AE38Q36067850-FB909F8B-1567-49EC-869F-EF0732252EE5Q38162181-C38BF82C-4EDE-497B-910A-3166E36FAE99Q38453650-7B753DB4-FDE9-4746-9316-0D8A6F94636AQ39948888-90C18867-E6AC-462E-BDB5-B9884EFC6C68Q52691915-DBCF0E6C-4A26-4570-975E-F81692E3C58EQ52737224-6EF7916D-5233-462E-9BFF-818DA659145C
P2860
Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immunogenicity of in vitro mai ...... ipotent stem cell derivatives.
@en
type
label
Immunogenicity of in vitro mai ...... ipotent stem cell derivatives.
@en
prefLabel
Immunogenicity of in vitro mai ...... ipotent stem cell derivatives.
@en
P2093
P2860
P1476
Immunogenicity of in vitro mai ...... ipotent stem cell derivatives.
@en
P2093
Irving L Weissman
Micha Drukker
P2860
P356
10.1007/978-1-62703-478-4_2
P407
P577
2013-01-01T00:00:00Z